Clinical Development & Research

Pre-ClinicalPhase IPhase IIPhase IIICommercialisation

Medi-Solfen® Human (Lacerations)

2025 phase II		Phase 1b (Part 1) completed 2026Phase 2a (Part 2) planned 2027.Target 2028Target 2031

Medi-Solfen® Human (Venous Leg Ulcers)

Q3 2026 phase II		PlannedTarget 2029Target 2031

Medi-Solfen® Human (Post Procedure Pain Relief)

Phase I		PlannedTarget 2029Target 2030Target 2031

Medi-Solfen® Human (Paediatric)*

Pre-Clinical		Target 2029Target 2030Target 2032Target 2033
In-house / available for partnering

* Studies as part of Paediatric Investigation Plan: Pre-Clinical

Recent scientific journals

  • Journal of Military and Veterans’ Health
    2026

    Initial Human Trial of an Established Australian Veterinary Formulation, Used on Major Wounds to Deliver Rapid and Prolonged Pain Relief

    Sheil and Jeffery on the first-in-human trial of Medi-Solfen for battle wounds (conference abstract October 2026, pp 152 to 153)
  • International Wound Journal
    2019

    Innovative pain management solutions in animals may provide improved wound pain reduction during debridement in humans

    Christopher D. Roberts, Peter A Windsor
  • Wounds UK
    2019

    Development of a UK cost analysis model for the various methods of debriding leg ulcers

    C. Roberts et al
Click Here
Click Here
Click Here

USA Department of Defense

  • USDOD Peer Review
    2020

    A topical anaesthetic wound care agent to be used for frontline pain management of acute traumatic wounds

    The Summary Paper is available on request

Medi-Solfen Pty Ltd has the commercial rights to 40+ patents in key global markets, with several new patents pending, providing protection until 2041.

See a full list of our patents, distribution partners and opportunities in our corporate profile document.

Download